GB2596411B - Compositions and methods comprising IgA antibody constructs - Google Patents

Compositions and methods comprising IgA antibody constructs Download PDF

Info

Publication number
GB2596411B
GB2596411B GB2107478.6A GB202107478A GB2596411B GB 2596411 B GB2596411 B GB 2596411B GB 202107478 A GB202107478 A GB 202107478A GB 2596411 B GB2596411 B GB 2596411B
Authority
GB
United Kingdom
Prior art keywords
compositions
methods
antibody constructs
iga antibody
iga
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB2107478.6A
Other languages
English (en)
Other versions
GB202107478D0 (en
GB2596411A (en
Inventor
De Boer Mark
Henrica Wilhelmina Leusen Jeannette
Jan Van Tetering Geert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UMC Utrecht Holding BV
TigaTx Inc
Original Assignee
UMC Utrecht Holding BV
TigaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UMC Utrecht Holding BV, TigaTx Inc filed Critical UMC Utrecht Holding BV
Publication of GB202107478D0 publication Critical patent/GB202107478D0/en
Publication of GB2596411A publication Critical patent/GB2596411A/en
Application granted granted Critical
Publication of GB2596411B publication Critical patent/GB2596411B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB2107478.6A 2018-10-29 2019-10-29 Compositions and methods comprising IgA antibody constructs Active GB2596411B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18203183 2018-10-29
US201862752641P 2018-10-30 2018-10-30
PCT/US2019/058648 WO2020092427A1 (en) 2018-10-29 2019-10-29 COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS

Publications (3)

Publication Number Publication Date
GB202107478D0 GB202107478D0 (en) 2021-07-07
GB2596411A GB2596411A (en) 2021-12-29
GB2596411B true GB2596411B (en) 2023-09-20

Family

ID=70462698

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2107478.6A Active GB2596411B (en) 2018-10-29 2019-10-29 Compositions and methods comprising IgA antibody constructs

Country Status (9)

Country Link
US (1) US20210332131A1 (https=)
EP (1) EP3873942A4 (https=)
JP (2) JP2022506761A (https=)
KR (1) KR20210096612A (https=)
CN (1) CN113260632A (https=)
AU (1) AU2019369397A1 (https=)
CA (1) CA3118312A1 (https=)
GB (1) GB2596411B (https=)
WO (1) WO2020092427A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220004979A (ko) * 2019-03-27 2022-01-12 유엠씨 우트레크트 홀딩 비.브이. 조작된 iga 항체 및 사용 방법
CA3196402A1 (en) * 2020-10-22 2022-04-28 Dale L. Ludwig Combination radioimmunotherapy and cd47 blockade in the treatment of cancer
WO2022125439A2 (en) * 2020-12-07 2022-06-16 The Regents Of The University Of California Innate immune cell silencing by sirp-alpha engager
CN116731161A (zh) * 2021-09-18 2023-09-12 南开大学 工程化IgG和IgA嵌合的“四叶草型X抗体”
WO2023154730A2 (en) * 2022-02-09 2023-08-17 Exelixis, Inc. Multispecific binding agents and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
WO2014087248A2 (en) * 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
WO2018044172A1 (en) * 2016-09-01 2018-03-08 Umc Utrecht Holding B.V. Cd20 antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0226878D0 (en) * 2002-11-18 2002-12-24 Univ Warwick Antibodies
ES2672640T3 (es) * 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
EP2477648B1 (en) * 2009-09-15 2022-07-20 The Board of Trustees of the Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2013087912A1 (en) * 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US20140213771A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Multi-specific binding proteins
AU2014227638A1 (en) * 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
US10087257B2 (en) * 2014-08-08 2018-10-02 The Board Of Trustees Of The Leland Stanford Junior University SIRP alpha-antibody fusion proteins
HUE046661T2 (hu) * 2014-08-15 2020-03-30 Merck Patent Gmbh SIRP-alfa immunglobulin fúziós proteinek
NZ741324A (en) * 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use
CN107459579B (zh) * 2016-06-01 2021-09-24 泰州迈博太科药业有限公司 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用
EP3574009A4 (en) * 2017-01-26 2020-11-25 Zlip Holding Limited CD47 ANTIGEN BINDING UNIT AND ITS USES
AU2018308191B2 (en) * 2017-07-24 2023-12-21 Scenic Immunology B.V. Treating pathological conditions by direct and indirect targeting of SIRPa - CD47 interaction
ES2933256T3 (es) * 2017-08-08 2023-02-03 Hoffmann La Roche Tratamiento con obinutuzumab de un subgrupo de pacientes con LDLBG

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010035012A1 (en) * 2008-09-26 2010-04-01 Ucb Pharma S.A. Biological products
WO2014087248A2 (en) * 2012-12-03 2014-06-12 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
WO2018044172A1 (en) * 2016-09-01 2018-03-08 Umc Utrecht Holding B.V. Cd20 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN BOMMEL, PE, et al. CD20-Selective Inhibition of CD47-SIRP-alpha 'Don't Eat Me' Signaling With A Bispecific Antibody-Derivative Enhances The Anticancer Activity of Daratumab, Alemtuzumab and Obinutuzumab. Oncoimmunology. 31 October 2017, Vol. 7, No. 2; e1386361; https://doi.org/10.1080/2162402X.2 *

Also Published As

Publication number Publication date
CA3118312A1 (en) 2020-05-07
EP3873942A4 (en) 2022-12-28
EP3873942A1 (en) 2021-09-08
GB202107478D0 (en) 2021-07-07
JP2024170456A (ja) 2024-12-10
JP2022506761A (ja) 2022-01-17
KR20210096612A (ko) 2021-08-05
CN113260632A (zh) 2021-08-13
US20210332131A1 (en) 2021-10-28
WO2020092427A1 (en) 2020-05-07
GB2596411A (en) 2021-12-29
AU2019369397A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
IL280963A (en) Anti-5gdf1 antibodies, compounds and methods of use
ZA202102034B (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
IL282968A (en) Anti-NKG2A antibodies and their use
IL278061A (en) Structures of antibodies against ROR
IL276950A (en) Anti-CD73 antibodies and uses thereof
SG11202100888WA (en) Anti-avb8 antibodies and compositions and uses thereof
IL265844A (en) Anti-lag-3 antibodies and preparations
IL290141A (en) Formulations of anti-pvrig antibodies and uses thereof
IL262176A (en) Anti-tim-3 antibodies and preparations
GB2596411B (en) Compositions and methods comprising IgA antibody constructs
SG11202104240TA (en) Cll1-targeting antibody and application thereof
IL275826A (en) Anti-mct1 antibodies and their uses
IL274809A (en) Antibodies against CXCR5 and their preparations and uses
ZA202006263B (en) Antibody formulation
IL278466B1 (en) Anti-dll3 antibodies and uses thereof
IL280321A (en) Antibodies against CXCR2 and their uses
SG11202103064YA (en) Antibody formulation
IL281202A (en) Anti-TNFRSF9 antibodies and uses thereof
IL281129A (en) Methods and compositions containing B7H3 chimeric antigen receptors
IL277075A (en) Anti-PHF-tau antibodies and uses thereof
IL288685A (en) Antigen-binding protein structures and uses thereof
IL277330A (en) Anti-IL-27 antibodies and uses thereof
IL276548A (en) Binding antibodies - BCMA and their uses
SG11202104300PA (en) Antibody formulation
SG11202102875YA (en) Anti-fgfr2 antibody formulations